Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Emmanuel Seront, MD, PhD, Jolimont Hospital, La Louvière, Belgium, outlines the use of genomic testing in prostate cancer as well as abnormalities seen in these patients that influence prognosis including BRCA mutated patients that can be targeted using olaparib. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).